By Finance Pulse in KeyInfo —

Johnson & Johnson's Lung Cancer Therapy Surpasses AstraZeneca's Tagrisso

Johnson & Johnson's combination therapy outperforms AstraZeneca's Tagrisso in a pivotal lung cancer study. Discover the latest advancements in cancer treatments.

A sleek, modern depiction of lung cancer cells under a microscope, highlighted with contrasting colo
Johnson & Johnson's Lung Cancer Therapy Surpasses AstraZeneca's Tagrisso

Johnson & Johnson announced that its combination therapy for lung cancer outperformed AstraZeneca's Tagrisso in a head-to-head study.

Source